Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: KMT2E

Summary for KMT2E

Gene information	Gene symbol	KMT2E
	Ensembl ID	ENSG00000005483
	Entrez ID	55904
	Gene name	lysine methyltransferase 2E (inactive)
	Synonyms	HDCMC04P\|MLL5\|SETD5B
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: KMT2E

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.284891	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.277416	1.97e-31
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.31082	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.288482	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.250521	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	0.497208	4.32e-03
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.280537	1.67e-16
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.252757	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.539159	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.406578	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.315754	1.51e-39
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.519521	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.549327	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-0.758971	1.08e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.462402	0.00e+00
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.277504	9.11e-36

Top

Expression of KMT2E in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to KMT2E

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating KMT2E

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
KMT2E	hsa-miR-10527-5p	96.9931	NM_018682
KMT2E	hsa-miR-1252-3p	96.2733	NM_018682
KMT2E	hsa-miR-3163	95.459	NM_018682
KMT2E	hsa-miR-5580-3p	95.3021	NM_182931
KMT2E	hsa-miR-1284	94.7439	NM_018682
KMT2E	hsa-miR-1825	94.658	NM_018682
KMT2E	hsa-miR-548e-5p	94.5784	NM_018682
KMT2E	hsa-miR-450b-5p	93.8377	NM_018682
KMT2E	hsa-miR-6719-3p	93.3854	NM_182931
KMT2E	hsa-let-7c-3p	93.2493	NM_018682
KMT2E	hsa-miR-12136	91.711	NM_182931
KMT2E	hsa-miR-548p	91.073	NM_182931
KMT2E	hsa-miR-542-3p	90.045	NM_182931
KMT2E	hsa-miR-600	89.2196	NM_182931
KMT2E	hsa-miR-190b-3p	88.5093	NM_018682
KMT2E	hsa-miR-4768-3p	88.2719	NM_182931
KMT2E	hsa-miR-33a-3p	88.2642	NM_018682
KMT2E	hsa-miR-3646	88.0975	NM_018682
KMT2E	hsa-miR-33b-5p	87.902	NM_018682
KMT2E	hsa-miR-33a-5p	87.902	NM_018682
KMT2E	hsa-miR-888-3p	87.8279	NM_182931
KMT2E	hsa-miR-206	87.5286	NM_018682
KMT2E	hsa-miR-1-3p	87.5286	NM_018682
KMT2E	hsa-miR-19b-2-5p	87.044	NM_018682
KMT2E	hsa-miR-19a-5p	87.044	NM_018682
KMT2E	hsa-miR-19b-1-5p	87.044	NM_018682
KMT2E	hsa-miR-548aj-5p	86.9731	NM_182931
KMT2E	hsa-miR-548g-5p	86.9731	NM_182931
KMT2E	hsa-miR-548x-5p	86.9731	NM_182931
KMT2E	hsa-miR-4327	86.6534	NM_182931
KMT2E	hsa-miR-16-1-3p	86.5433	NM_018682
KMT2E	hsa-miR-6516-3p	86.4382	NM_018682
KMT2E	hsa-miR-200b-5p	86.1833	NM_182931
KMT2E	hsa-miR-200a-5p	86.1833	NM_182931
KMT2E	hsa-miR-892b	85.5223	NM_018682
KMT2E	hsa-miR-582-5p	85.3436	NM_018682
KMT2E	hsa-miR-4302	84.626	NM_182931
KMT2E	hsa-miR-613	84.4234	NM_018682
KMT2E	hsa-miR-548aw	84.1838	NM_182931
KMT2E	hsa-miR-582-3p	84.0938	NM_182931
KMT2E	hsa-miR-548f-5p	83.6754	NM_182931
KMT2E	hsa-miR-568	82.5086	NM_182931
KMT2E	hsa-miR-3143	82.3391	NM_182931
KMT2E	hsa-miR-12129	81.9235	NM_018682

Page: 1

Top

Motifs and transcription factors (TFs) regulating KMT2E

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
KMT2E	metacluster_7.13	ZFX (directAnnotation).
KMT2E	metacluster_174.2	CEBPZ; CEBPZ; DRAP1; FOS; FOXI1; FOXI1; HMGXB3; IRF3; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYB; NFYB; NFYB; NFYB; NFYB; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; PBX3; PBX3; SP2 (directAnnotation). NFYA; NFYA; NFYC; PBX1; PBX3 (inferredBy_Orthology).
KMT2E	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	ETS2 (directAnnotation).
KMT2E	metacluster_151.2	ZNF23 (directAnnotation).
KMT2E	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
KMT2E	transfac_pro__M05479	ZNF580 (directAnnotation).
KMT2E	metacluster_155.23	BCL11B; ZNF711; ZNF711 (directAnnotation). ZFY (inferredBy_Orthology).
KMT2E	hdpi__ETV4	ETV4 (directAnnotation).
KMT2E	transfac_pro__M06071	ZNF814 (directAnnotation).
KMT2E	homer__TWVGGTCCGC_HINFP	HINFP (directAnnotation).
KMT2E	metacluster_135.10	MBD2; MBD2; MECP2; MECP2 (directAnnotation).
KMT2E	jaspar__MA0079.5	SP1 (directAnnotation).
KMT2E	transfac_pro__M04826	EP300 (directAnnotation).
KMT2E	taipale_tf_pairs__HOXB2_ELK3_RSCGGAAGTMRTTA_CAP	ELK3; HOXB2 (directAnnotation).
KMT2E	taipale_tf_pairs__HOXB2_ELF1_SMGGAAGTMRTTA_CAP	ELF1; HOXB2 (directAnnotation).
KMT2E	taipale_tf_pairs__ELK1_HOXA1_RCCGGAAGTAATTA_HT	ELK1; HOXA1 (directAnnotation).
KMT2E	transfac_pro__M06951	TEF (directAnnotation).
KMT2E	hdpi__HIP2	UBE2K (directAnnotation).
KMT2E	jaspar__MA1957.1	ELK1 (directAnnotation).
KMT2E	taipale_tf_pairs__ETV2_HOXA2_NCCGGAAGTMATTA_CAP_repr	ETV2; HOXA2 (directAnnotation).
KMT2E	transfac_pro__M00733	SMAD4 (directAnnotation).
KMT2E	transfac_pro__M07387	ZBTB7A (directAnnotation).
KMT2E	taipale_tf_pairs__TEAD4_ELK3_NCCGGAANNNNNNNMATWCC_CAP_repr	ELK3; TEAD4 (directAnnotation).
KMT2E	transfac_public__M00189	TFAP2A; TFAP2B; TFAP2C (directAnnotation).
KMT2E	transfac_pro__M00716	ZBTB14 (directAnnotation).
KMT2E	cisbp__M00343	PAX6 (directAnnotation).
KMT2E	hdpi__NRL	NRL (directAnnotation).
KMT2E	swissregulon__hs__CHD1	CHD1 (directAnnotation).
KMT2E	transfac_pro__M00915	TFAP2A; TFAP2B; TFAP2C (directAnnotation).
KMT2E	transfac_pro__M04916	TAF1 (directAnnotation).
KMT2E	transfac_pro__M04617	ZBTB7A (directAnnotation).
KMT2E	transfac_pro__M07611	NONO (directAnnotation).
KMT2E	transfac_pro__M01088	DEAF1 (inferredBy_Orthology).
KMT2E	transfac_pro__M02898	SMAD3 (directAnnotation).
KMT2E	metacluster_61.1	DEAF1; DEAF1 (directAnnotation).
KMT2E	metacluster_24.1	HIC1; HIC1; ZNF816; ZNF816; ZNF816; ZXDC (directAnnotation).
KMT2E	metacluster_66.2	ZNF530; ZNF530; ZNF534; ZNF534; ZNF662; ZNF662 (directAnnotation).
KMT2E	taipale_cyt_meth__GCM1_RTGCGGGTN_eDBD	GCM1 (directAnnotation).
KMT2E	metacluster_126.7	CTCF; ZFY; ZSCAN30 (directAnnotation).
KMT2E	metacluster_115.1	NEUROD1; PHF1; ZBTB20; ZNF17; ZNF296; ZNF350; ZNF486; ZNF574; ZNF589; ZNF891 (directAnnotation). IRF4; IRF6; PRDM5 (inferredBy_Orthology).
KMT2E	metacluster_151.1	KAT7; PML; SMAD5; TAF1; ZFP37; ZGPAT; ZNF519; ZNF519; ZNF571; ZNF770; ZNF770; ZNF770; ZSCAN22; ZSCAN22 (directAnnotation).
KMT2E	transfac_pro__M12694	ZFP14 (directAnnotation).
KMT2E	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
KMT2E	metacluster_141.6	MZF1; TAF1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZNF597 (directAnnotation). TAF1; TAF1L (inferredBy_Orthology).
KMT2E	transfac_pro__M02913	SP140 (inferredBy_Orthology).
KMT2E	jaspar__MA0185.1	DEAF1 (inferredBy_Orthology).
KMT2E	jaspar__MA0748.2	YY2 (directAnnotation).
KMT2E	transfac_pro__M01090	SMAD9 (inferredBy_Orthology).
KMT2E	flyfactorsurvey__Mad_FlyReg_FBgn0011648	SMAD9 (inferredBy_Orthology).
KMT2E	cisbp__M00788	ZFY (inferredBy_Orthology).

Page: 1 2 3 4 5

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."